Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group.
González-Cordón A, et al. Among authors: guaraldi g.
J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247.
J Antimicrob Chemother. 2023.
PMID: 37539492